Dynavax Technologies (DVAX) Raised to Hold at ValuEngine

Dynavax Technologies (NASDAQ:DVAX) was upgraded by equities researchers at ValuEngine from a “sell” rating to a “hold” rating in a research note issued on Thursday.

A number of other analysts have also commented on DVAX. Zacks Investment Research raised shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a research report on Tuesday, July 24th. BidaskClub downgraded shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a report on Wednesday, August 1st. Cantor Fitzgerald restated a “buy” rating and set a $30.00 target price on shares of Dynavax Technologies in a report on Monday, August 6th. Royal Bank of Canada boosted their target price on shares of Dynavax Technologies to $26.00 and gave the stock an “outperform” rating in a report on Monday, October 22nd. Finally, Cowen restated a “buy” rating and set a $30.00 target price on shares of Dynavax Technologies in a report on Monday, October 22nd. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $28.00.

Shares of DVAX stock opened at $12.09 on Thursday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 8.67 and a current ratio of 8.87. The firm has a market capitalization of $756.69 million, a PE ratio of -6.99 and a beta of 0.61. Dynavax Technologies has a 12 month low of $9.63 and a 12 month high of $22.80.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings data on Monday, November 5th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.57) by ($0.08). The business had revenue of $1.46 million during the quarter, compared to the consensus estimate of $3.16 million. Dynavax Technologies had a negative return on equity of 87.67% and a negative net margin of 5,044.85%. The business’s revenue for the quarter was up 2822.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.38) EPS. Analysts anticipate that Dynavax Technologies will post -2.49 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Wells Fargo & Company MN increased its holdings in shares of Dynavax Technologies by 9.2% in the first quarter. Wells Fargo & Company MN now owns 45,516 shares of the biopharmaceutical company’s stock valued at $903,000 after purchasing an additional 3,834 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Dynavax Technologies by 1.8% in the third quarter. JPMorgan Chase & Co. now owns 264,669 shares of the biopharmaceutical company’s stock valued at $3,282,000 after purchasing an additional 4,591 shares during the last quarter. Creative Planning increased its holdings in shares of Dynavax Technologies by 2.6% in the second quarter. Creative Planning now owns 235,105 shares of the biopharmaceutical company’s stock valued at $3,585,000 after purchasing an additional 5,857 shares during the last quarter. Guggenheim Capital LLC increased its holdings in shares of Dynavax Technologies by 7.2% in the first quarter. Guggenheim Capital LLC now owns 112,278 shares of the biopharmaceutical company’s stock valued at $2,228,000 after purchasing an additional 7,522 shares during the last quarter. Finally, Patriot Financial Group Insurance Agency LLC increased its holdings in shares of Dynavax Technologies by 39.2% in the third quarter. Patriot Financial Group Insurance Agency LLC now owns 29,170 shares of the biopharmaceutical company’s stock valued at $362,000 after purchasing an additional 8,220 shares during the last quarter. Institutional investors and hedge funds own 81.48% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.

Featured Article: What factors cause inflation to rise?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply